


Personalized medicine approach to treating AML

The Leukemia & Lymphoma Society (LLS) and the Knight Cancer Institute at Oregon Health & Science University are leading a pioneering collaboration to develop a precision medicine approach to improve outcomes for patients with acute myeloid leukemia (AML), a particularly devastating cancer of the blood and bone marrow. LLS provided \$8.2 million to fund Beat AML and here is how the collaboration will work:

Beat AML

- 
- 1 In coordination with the Knight Cancer Institute, Stanford University, UT Southwestern Medical Center and Huntsman Cancer Institute will collect data from 900 AML patient samples within 3 years.



- 2 Illumina will perform genetic sequencing to identify mutations in the patient samples collected.



- 4 Drug and biotech companies will work with the collaboration to test drug compounds that target mutations suspected of driving disease progression. Array BioPharma will be first to test a therapeutic.



- 3 Intel will work with Knight Cancer's bioinformatics team to apply its technology to accelerate computational analysis of the mutation data collected.